Hammond David, Goodman Samantha
School of Public Health and Health Systems, University of Waterloo, Waterloo, Canada.
Cannabis Cannabinoid Res. 2022 Jun;7(3):345-354. doi: 10.1089/can.2020.0092. Epub 2020 Oct 29.
This study aimed to examine consumer knowledge of tetrahydrocannabinol (THC) and cannabidiol (CBD) levels for usual cannabis products. Data are from the International Cannabis Policy Study conducted online in August-September 2018. Respondents included 6471 past 12-month cannabis users, aged 16-65 years, recruited from the Nielsen Global Insights Consumer Panel using nonprobability methods. Respondents were recruited from Canada, which had not yet legalized nonmedical cannabis (=2354), and US states that had (=2160) and had not (=1957) legalized nonmedical cannabis. Participants reported descriptive THC:CBD ratios (e.g., high THC, low CBD) and numeric THC and CBD levels (mg or %) for products they usually use in each of nine product categories. Few consumers knew and were able to report the numeric THC or CBD levels of their usual cannabis products. For example, only 10% of dried herb consumers reported the THC level, approximately 30% of whom reported implausible values. A greater proportion of consumers reported a descriptive THC:CBD ratio of their usual product, ranging from 50.9% of edible users to 78.2% of orally ingested oil users. Consumers were substantially more likely to report products high in THC versus low in THC for all products except topicals and tinctures, whereas similar proportions reported using products high and low in CBD. Despite some evidence of greater knowledge in legal jurisdictions, knowledge was still low in states with legal cannabis markets. Consumer knowledge of THC and CBD levels was low, with only modest differences between consumers living in jurisdictions that had and had not legalized nonmedical cannabis. The findings cast doubt on the validity of self-reported cannabinoid levels.
本研究旨在调查消费者对常见大麻产品中四氢大麻酚(THC)和大麻二酚(CBD)含量的了解情况。数据来自于2018年8月至9月在线开展的国际大麻政策研究。受访者包括6471名过去12个月内使用过大麻的用户,年龄在16至65岁之间,通过非概率抽样方法从尼尔森全球消费者洞察小组招募而来。受访者来自加拿大(尚未将非医用大麻合法化,n = 2354)以及美国已将非医用大麻合法化(n = 2160)和未合法化(n = 1957)的州。参与者报告了他们通常使用的九种产品类别中每种产品的THC:CBD描述性比例(例如,高THC、低CBD)以及THC和CBD的具体含量(毫克或百分比)。很少有消费者知道并能够报告他们常用大麻产品的THC或CBD具体含量。例如,只有10%的干草药消费者报告了THC含量,其中约30%报告的值不合理。更大比例的消费者报告了他们常用产品的THC:CBD描述性比例,范围从食用产品用户的50.9%到口服油类产品用户的78.2%。除了外用产品和酊剂外,消费者报告使用高THC产品的可能性显著高于低THC产品,而报告使用高CBD和低CBD产品的比例相近。尽管有证据表明在大麻合法化的司法管辖区消费者了解程度更高,但在有合法大麻市场的州,了解程度仍然较低。消费者对THC和CBD含量的了解程度较低,生活在非医用大麻已合法化和未合法化司法管辖区的消费者之间差异不大。这些发现对自我报告的大麻素含量的有效性提出了质疑。